NA PCR-based Infectious Diseases Market - Industry Trends and Forecast to 2035

Description

List of Tables

The North America PCR-based infectious diseases market is expected to reach USD 2,466,991.74 thousand by 2031 from USD 1,437,378.74 thousand in 2023, growing with a CAGR of 7.2% in the forecast period of 2024 to 2031.

Market Segmentation

North America PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031

Overview of North America PCR-based Infectious Diseases Market Dynamics

Driver
Increasing PCR-based research activities
Restraint
High cost of PCR test services
Opportunity
Disease surveillance for early detection and monitoring of infectious diseases

Market Players

Some of the major market players operating in the North America PCR-based infectious diseases market are:

DNA Labs India
DrSafeHands
Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
Max Lab
MicroGen Diagnostics
pathlab
The Washington Travel Clinic
Clarewell Clinics
AZOVA
One Life Home Health Care Center
LalPathLabs

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET 17
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 19
1.6 MARKETS COVERED 19

2 MARKET SEGMENTATION 22

2.1 MARKETS COVERED 22
2.2 GEOGRAPHICAL SCOPE 23
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 DBMR TRIPOD DATA VALIDATION MODEL 25
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.6 MULTIVARIATE MODELLING 29
2.7 MARKET APPLICATION COVERAGE GRID 30
2.8 TEST TYPE LIFELINE CURVE 31
2.9 DBMR MARKET POSITION GRID 32
2.10 VENDOR SHARE ANALYSIS 33
2.11 SECONDARY SOURCES 34
2.12 ASSUMPTIONS 34

3 EXECUTIVE SUMMARY 35

4 PREMIUM INSIGHTS 38

4.1 PESTEL ANALYSIS 39
4.2 PORTER'S FIVE FORCES 40

5 MARKET OVERVIEW 41

5.1 DRIVERS 43
- 5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 43
- 5.1.2 RISING CASES OF INFECTIOUS DISEASES 43
- 5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 44
5.2 RESTRAINTS 45
- 5.2.1 HIGH COST OF PCR TEST SERVICES 45
- 5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 46
5.3 OPPORTUNITIES 47
- 5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 47
- 5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 47
- 5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 48
5.4 CHALLENGES 49
- 5.4.1 DATA SECURITY AND PRIVACY CONCERNS 49
- 5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 49

6 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 51

6.1 OVERVIEW 52
6.2 TUBERCULOSIS PCR TEST 58
6.3 HEPATITIS PCR TEST 58
- 6.3.1 HEPATITIS C PCR TEST 59
- 6.3.2 HEPATITIS B PCR TEST 59
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 60
6.5 INFLUENZA PCR TEST 60
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 61
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 61
6.8 GONORRHEA PCR TEST 62
6.9 SALMONELLOSIS PCR TEST 62
6.10 ROTAVIRUS PCR TEST 63
6.11 BORDETELLA PCR TEST 63
6.12 H. PYLORI PCR TEST 64
6.13 SARS (COVID-19) PCR TEST 64
6.14 NOROVIRUS PCR TEST 65
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 65
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 66
6.17 ENTEROCOCCUS PCR TEST 66
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 67
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 67
6.20 OTHERS PCR TEST 68

7 NORTH AMERICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 69

7.1 OVERVIEW 70
7.2 VIRAL INFECTION 73
- 7.2.1 SARS (COVID-19) INFECTION 73
- 7.2.2 ROTAVIRUS INFECTION 73
- 7.2.3 NOROVIRUS INFECTION 73
- 7.2.4 OTHERS 74
7.3 RESPIRATORY TRACT INFECTION 74
- 7.3.1 INFLUENZA 74
- 7.3.2 TUBERCULOSIS 74
- 7.3.3 BORDETELLA 75
7.4 SEXUALLY TRANSMITTED INFECTION 75
- 7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 76
- 7.4.2 GONORRHEA 76
- 7.4.3 HEAPTITIS 76
- 7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 76
- 7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 76
- 7.4.6 MYCOPLASMA GENITALIUM (MG) 76
- 7.4.7 OTHERS 76
7.5 HOSPITAL ACQUIRED INFECTIONS 77
- 7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 77
- 7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 77
- 7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 78
- 7.5.4 OTHERS 78
7.6 OTHER INFECTIONS 78
- 7.6.1 SALMONELLOSIS 78
- 7.6.2 H. PYLORI 79
- 7.6.3 ENTEROCOCCUS INFECTIONS 79
- 7.6.4 OTHERS 79

8 NORTH AMERICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 80

8.1 OVERVIEW 81
8.2 VIRAL 84
8.3 BACTERIAL 84
8.4 FUNGAL 85
8.5 PROTOZOA 85
8.6 OTHERS 86

9 NORTH AMERICA PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 87

9.1 OVERVIEW 88
9.2 RT PCR 91
9.3 MULTIPLEX PCR 91
9.4 OTHERS 92

10 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 93

10.1 OVERVIEW 94
10.2 GERIATRIC 97
10.3 PEDIATRIC 97
10.4 ADULTS 98

11 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 99

11.1 OVERVIEW 100
11.2 LABORATORY BASED TESTING 103
11.3 POINT OF CARE TESTING 103

12 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 104

12.1 OVERVIEW 105
12.2 DIAGNOSTIC CENTERS 108
12.3 HOSPITAL 108
12.4 CLINICS 109
12.5 COMMUNITY HEALTH CENTERS 109
12.6 ACADEMIC AND RESEARCH INSTITUTES 110
12.7 HOME HEALTHCARE 110
12.8 OTHERS 111

13 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 112

13.1 NORTH AMERICA 115
- 13.1.1 U.S. 124
- 13.1.2 CANADA 132
- 13.1.3 MEXICO 140

14 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 148

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 148

15 SWOT ANALYSIS 149

16 COMPANY PROFILE 150

16.1 MICROGEN DIAGNOSTICS 150
- 16.1.1 COMPANY SNAPSHOT 150
- 16.1.2 SERVICE PORTFOLIO 150
- 16.1.3 RECENT DEVELOPMENTS 151
16.2 MAX LAB 152
- 16.2.1 COMPANY SNAPSHOT 152
- 16.2.2 SERVICE PORTFOLIO 152
16.3 DNA LABS INDIA 154
- 16.3.1 COMPANY SNAPSHOT 154
- 16.3.2 SERVICE PORTFOLIO 154
- 16.3.3 RECENT DEVELOPMENT 155
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD. 156
- 16.4.1 COMPANY SNAPSHOT 156
- 16.4.2 SERVICE PORTFOLIO 156
- 16.4.3 RECENT DEVELOPMENT 157
16.5 LALPATHLABS 158
- 16.5.1 COMPANY SNAPSHOT 158
- 16.5.2 REVENUE ANALYSIS 158
- 16.5.3 PRODUCT PORTFOLIO 159
- 16.5.4 RECENT DEVELOPMENTS 159
16.6 AZOVA 160
- 16.6.1 COMPANY SNAPSHOT 160
- 16.6.2 PRODUCT PORTFOLIO 160
- 16.6.3 RECENT DEVELOPMENTS 160
16.7 CLAREWELL CLINICS 161
- 16.7.1 COMPANY SNAPSHOT 161
- 16.7.2 PRODUCT DESCRIPTION 161
- 16.7.3 RECENT DEVELOPMENTS 161
16.8 DRSAFEHANDS 162
- 16.8.1 COMPANY SNAPSHOT 162
- 16.8.2 SERVICE PORTFOLIO 162
- 16.8.3 RECENT DEVELOPMENT 162
16.9 ONE LIFE HOME HEALTH CARE CENTER 163
- 16.9.1 COMPANY SNAPSHOT 163
- 16.9.2 PRODUCT DESCRIPTION 163
- 16.9.3 RECENT DEVELOPMENTS 163
16.10 PATHLAB 164
- 16.10.1 COMPANY SNAPSHOT 164
- 16.10.2 SERVICE PORTFOLIO 164
- 16.10.3 RECENT DEVELOPMENT 164
16.11 THE WASHINGTON TRAVEL CLINIC 165
- 16.11.1 COMPANY SNAPSHOT 165
- 16.11.2 SERVICE PORTFOLIO 165
- 16.11.3 RECENT DEVELOPMENT 166

17 QUESTIONNAIRE 167

18 RELATED REPORTS 171

LIST OF TABLES

TABLE 1 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 55
TABLE 2 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 56
TABLE 3 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 57
TABLE 4 NORTH AMERICA TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 58
TABLE 5 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 58
TABLE 6 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 59
TABLE 7 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 59
TABLE 8 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 59
TABLE 9 NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 60
TABLE 10 NORTH AMERICA INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 60
TABLE 11 NORTH AMERICA HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 61
TABLE 12 NORTH AMERICA CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 61
TABLE 13 NORTH AMERICA GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 62
TABLE 14 NORTH AMERICA SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 62
TABLE 15 NORTH AMERICA ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 63
TABLE 16 NORTH AMERICA BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 63
TABLE 17 NORTH AMERICA H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 18 NORTH AMERICA SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 19 NORTH AMERICA NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 65
TABLE 20 NORTH AMERICA C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 65
TABLE 21 NORTH AMERICA CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 22 NORTH AMERICA ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 23 NORTH AMERICA MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 24 NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 25 NORTH AMERICA OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 68
TABLE 26 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 72
TABLE 27 NORTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 73
TABLE 28 NORTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 73
TABLE 29 NORTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 74
TABLE 30 NORTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 74
TABLE 31 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 75
TABLE 32 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 75
TABLE 33 NORTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 77
TABLE 34 NORTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 77
TABLE 35 NORTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 78
TABLE 36 NORTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 78
TABLE 37 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 83
TABLE 38 NORTH AMERICA VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 84
TABLE 39 NORTH AMERICA BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 84
TABLE 40 NORTH AMERICA FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 85
TABLE 41 NORTH AMERICA PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 85
TABLE 42 NORTH AMERICA OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 86
TABLE 43 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 90
TABLE 44 NORTH AMERICA RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 45 NORTH AMERICA MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 46 NORTH AMERICA OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 92
TABLE 47 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 96
TABLE 48 NORTH AMERICA GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 49 NORTH AMERICA PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 50 NORTH AMERICA ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 98
TABLE 51 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 102
TABLE 52 NORTH AMERICA LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
TABLE 53 NORTH AMERICA POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
TABLE 54 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND) 107
TABLE 55 NORTH AMERICA DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 108
TABLE 56 NORTH AMERICA HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 108
TABLE 57 NORTH AMERICA CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 109
TABLE 58 NORTH AMERICA COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 109
TABLE 59 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 110
TABLE 60 NORTH AMERICA HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 110
TABLE 61 NORTH AMERICA OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 111
TABLE 62 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 115
TABLE 63 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 116
TABLE 64 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 117
TABLE 65 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 118
TABLE 66 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 119
TABLE 67 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 119
TABLE 68 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 119
TABLE 69 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 119
TABLE 70 NORTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 120
TABLE 71 NORTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 120
TABLE 72 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 121
TABLE 73 NORTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 121
TABLE 74 NORTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 122
TABLE 75 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 122
TABLE 76 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 122
TABLE 77 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 123
TABLE 78 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 123
TABLE 79 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 123
TABLE 80 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 124
TABLE 81 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 125
TABLE 82 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 126
TABLE 83 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 127
TABLE 84 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 127
TABLE 85 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 127
TABLE 86 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 127
TABLE 87 U.S. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 128
TABLE 88 U.S. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 128
TABLE 89 U.S. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 129
TABLE 90 U.S. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 129
TABLE 91 U.S. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 130
TABLE 92 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 130
TABLE 93 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 130
TABLE 94 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 131
TABLE 95 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 131
TABLE 96 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 131
TABLE 97 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 132
TABLE 98 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 133
TABLE 99 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 134
TABLE 100 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 135
TABLE 101 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 135
TABLE 102 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 135
TABLE 103 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 135
TABLE 104 CANADA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 136
TABLE 105 CANADA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 136
TABLE 106 CANADA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 137
TABLE 107 CANADA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 137
TABLE 108 CANADA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 138
TABLE 109 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 138
TABLE 110 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 138
TABLE 111 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 139
TABLE 112 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 139
TABLE 113 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 139
TABLE 114 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 140
TABLE 115 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 141
TABLE 116 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 142
TABLE 117 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 143
TABLE 118 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 143
TABLE 119 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 143
TABLE 120 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 143
TABLE 121 MEXICO VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 144
TABLE 122 MEXICO RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 144
TABLE 123 MEXICO SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 145
TABLE 124 MEXICO HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 145
TABLE 125 MEXICO OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 146
TABLE 126 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 146
TABLE 127 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 146
TABLE 128 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 147
TABLE 129 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 147
TABLE 130 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 147

LIST OF FIGURES

FIGURE 1 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 22
FIGURE 2 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 25
FIGURE 3 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS 26
FIGURE 4 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 27
FIGURE 5 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 30
FIGURE 8 NORTH AMERICA PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 32
FIGURE 9 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS 33
FIGURE 10 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 37
FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031 38
FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031 38
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET 42
FIGURE 14 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023 52
FIGURE 15 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND) 53
FIGURE 16 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031) 53
FIGURE 17 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE 54
FIGURE 18 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023 70
FIGURE 19 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND) 71
FIGURE 20 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031) 71
FIGURE 21 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE 72
FIGURE 22 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023 81
FIGURE 23 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND) 82
FIGURE 24 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031) 82
FIGURE 25 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE 83
FIGURE 26 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023 88
FIGURE 27 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND) 89
FIGURE 28 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031) 89
FIGURE 29 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE 90
FIGURE 30 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023 94
FIGURE 31 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND) 95
FIGURE 32 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031) 95
FIGURE 33 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE 96
FIGURE 34 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023 100
FIGURE 35 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND) 101
FIGURE 36 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031) 101
FIGURE 37 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE 102
FIGURE 38 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023 105
FIGURE 39 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND) 106
FIGURE 40 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031) 106
FIGURE 41 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE 107
FIGURE 42 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023) 113
FIGURE 43 NORTH AMERICA PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%) 148